Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
PDSC01 - Product Showcase
- 00:00 - 00:00
- 1/28/2021
- Location: Product Theater (via Industry Hub)
- Type: Product Showcases
- Track: N.A.
-
+
PDSC01.01 - 360° Perspectives on Biomarker Testing in Non-Small Cell Lung Cancer by PFIZER
00:00 - 00:00 | Presenter: Rasheda Persinger, Brendon Stiles, Tim Allen, Christine M. Lovly
- Abstract
No abstract available for this presentation
-
+
PDSC01.02 - Clinical Perspectives on the use of VIZIMPRO® (dacomitinib) as a First-line Treatment for Adults with Advanced or Metastatic NSCLC with EGFR-activating Mutations by PFIZER
00:00 - 00:00 | Presenter: Federico Cappuzzo
- Abstract
No abstract available for this presentation
-
+
PDSC01.03 - A 15 Min Catch Up on New Developments in NGS for Oncologists by THERMO FISHER SCIENTIFIC
00:00 - 00:00 | Presenter: Luca Quagliata
- Abstract
No abstract available for this presentation
-
+
JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC
- 07:00 - 09:00
- 1/28/2021
- Location: Scientific Program Auditorium
- Not for CME Credit
- Type: Workshop
- Track: N.A.
-
+
JICC01.01 - Chair
07:00 - 07:00 | Presenter: Yi-long Wu
- Abstract
No abstract available for this presentation
-
+
JICC01.02 - Chair
07:00 - 07:00 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
JICC01.03 - Chair
07:00 - 07:00 | Presenter: Chunxue Bai
- Abstract
No abstract available for this presentation
-
+
JICC01.04 - Chair
07:00 - 07:00 | Presenter: Caicun Zhou
- Abstract
No abstract available for this presentation
-
+
JICC01.05 - Single-Cell Sequencing Atlas of Tumor-associated Microvascular Endothelial Cell in Lung Cancer
07:00 - 07:15 | Presenter: Dawei Yang
- Abstract
No abstract available for this presentation
-
+
JICC01.06 - From Antibody to Small Molecule: What is the Difference?
07:15 - 07:30 | Presenter: Heather Wakelee
- Abstract
No abstract available for this presentation
-
+
JICC01.07 - Oral VEGFR Inhibitor Monotherapy for Lung Cancer: Should We or Should We Not?
07:30 - 07:45 | Presenter: Robert Pirker
- Abstract
Loading... -
+
JICC01.08 - Target Driver Gene and Target VEGFR: Could Prolong OS？
07:45 - 08:00 | Presenter: Ying Cheng
- Abstract
No abstract available for this presentation
-
+
JICC01.09 - Small Molecule Anti-VEGFR Combination with PD-1/PD-L1 Blockades: New Hope?
08:00 - 08:15 | Presenter: Shengxiang Ren
- Abstract
No abstract available for this presentation
-
+
JICC01.10 - Live Panel Discussion
08:15 - 08:25
- Abstract
No abstract available for this presentation
-
+
JICC01.11 - Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study
08:25 - 08:30 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
JICC01.12 - Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Chinese Advanced Non-Small Cell Lung Cancer
08:30 - 08:35 | Presenter: Xiaomin Niu
- Abstract
Loading... -
+
JICC01.13 - Discussant
08:35 - 08:40 | Presenter: Si-Yang Liu
- Abstract
No abstract available for this presentation
-
+
JICC01.14 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy
08:40 - 08:45 | Presenter: Qing Zhou
- Abstract
Loading... -
+
JICC01.15 - Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study
08:45 - 08:50 | Presenter: Yan Wang
- Abstract
Loading... -
+
JICC01.16 - Discussant: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC
08:50 - 08:55 | Presenter: Xiaorong Dong
- Abstract
No abstract available for this presentation
-
+
JICC01.17 - Live Panel Discussion
08:55 - 09:00
- Abstract
No abstract available for this presentation
-
+
IS01 - Satellite CME Symposium by Clinical Care Options: Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer
- 09:15 - 10:15
- 1/28/2021
- Location: Scientific Program Auditorium
- CME Accredited by Other Provider
- Type: Satellite CME Symposia
- Track:
-
+
IS01.01 - Welcome, Introduction and Baseline Assessment
09:15 - 09:20
- Abstract
No abstract available for this presentation
-
+
IS01.02 - Introduction to Novel Antibody–Drug Conjugates for Treatment of NSCLC
09:20 - 09:30
- Abstract
No abstract available for this presentation
-
+
IS01.03 - Presentation on Activity of ADCS in Clinical Trials for Lung Cancer
09:30 - 09:40
- Abstract
No abstract available for this presentation
-
+
IS01.04 - Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC
09:40 - 09:55
- Abstract
No abstract available for this presentation
-
+
IS01.05 - Panel Discussion and Q&A
09:55 - 10:10
- Abstract
No abstract available for this presentation
-
+
IS01.06 - Summary, Final Thoughts, Post Education Assessment and Q&A
10:10 - 10:15
- Abstract
No abstract available for this presentation
-
+
IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC
- 10:30 - 11:30
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS02.01 - Opening Remarks
10:30 - 10:35 | Presenter: Masahiro Tsuboi
- Abstract
No abstract available for this presentation
-
+
IS02.02 - Current Strategies for IO Therapy for Unresectable Stage III NSCLC
10:35 - 10:45 | Presenter: Glenwood Dillon Goss
- Abstract
No abstract available for this presentation
-
+
IS02.03 - Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC
10:45 - 10:55 | Presenter: Suresh Senan
- Abstract
No abstract available for this presentation
-
+
IS02.04 - Defining the Role of Immunotherapy in the Treatment of ES-SCLC
10:55 - 11:05 | Presenter: Myung-Ju Ahn
- Abstract
No abstract available for this presentation
-
+
IS02.05 - Emerging Biomarkers in SCLC
11:05 - 11:15 | Presenter: Charles M. Rudin
- Abstract
No abstract available for this presentation
-
+
IS02.06 - Panel Discussion / Q&A Panel Discussion
11:15 - 11:30
- Abstract
No abstract available for this presentation
-
+
IS03 - Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges
- 11:45 - 12:45
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS03.01 - Welcome and Introduction
11:45 - 11:50 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
IS03.02 - Evolving Challenges for the Treatment of Advanced NSCLC
11:50 - 12:00 | Presenter: Tony S. Mok
- Abstract
No abstract available for this presentation
-
+
IS03.03 - Emerging ADC Targets for the Treatment of Late-Line NSCLC
12:00 - 12:15 | Presenter: Pasi Antero Jänne
- Abstract
No abstract available for this presentation
-
+
IS03.04 - ADC Therapies as Targeted Treatment Options in Patients With Advanced NSCLC
12:15 - 12:30 | Presenter: James Chih-Hsin Yang
- Abstract
No abstract available for this presentation
-
+
IS03.05 - Interactive Q&A/Panel Discussion
12:30 - 12:45
- Abstract
No abstract available for this presentation
-
+
IS04 - Industry Symposium Sponsored by Lilly Oncology: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices
- 13:00 - 14:00
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS04.01 - Chair’s Welcome
13:00 - 13:04 | Presenter: Koichi Goto
- Abstract
No abstract available for this presentation
-
+
IS04.02 - Introduction to the Topic - A Brief Overview of the 15-Year Journey of Biomarker Driven Management of NSCLC
13:04 - 13:10 | Presenter: Koichi Goto
- Abstract
No abstract available for this presentation
-
+
IS04.03 - Developing Best Practices for the Accurate Diagnosis and Treatment of All Patients With NSCLC - Practical Tips on Optimising Diagnostic Capabilities in the Clinic
13:10 - 13:22 | Presenter: Herbert H Loong
- Abstract
No abstract available for this presentation
-
+
IS04.04 - The Roles of the Oncologist and Pathologist in Providing an Actionable Diagnosis - Discuss the Role of the Tumour Board / MDT in Implementing Precision Medicine
13:22 - 13:34 | Presenter: Fernando Lopez-Rios
- Abstract
No abstract available for this presentation
-
+
IS04.05 - Gaining Consensus - An Overview of the IASLC, NCCN and ESMO Guidelines for Treating and Testing Patients
13:34 - 13:44 | Presenter: Giuseppe Curigliano
- Abstract
No abstract available for this presentation
-
+
IS04.06 - Panel Discussion and Q&A
13:44 - 14:00
- Abstract
No abstract available for this presentation
-
+
IS04.07 - Symposium Close
14:00 - 14:00 | Presenter: Koichi Goto
- Abstract
No abstract available for this presentation
-
+
IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer
- 14:15 - 15:15
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS05.01 - Welcome and Introductions
14:15 - 14:15 | Presenter: Rina Hui
- Abstract
No abstract available for this presentation
-
+
IS05.02 - Frontline Immunotherapy Treatment Options in mNSCLC
14:15 - 14:30 | Presenter: Rina Hui
- Abstract
No abstract available for this presentation
-
+
IS05.03 - Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer
14:30 - 14:45 | Presenter: Roy S. Herbst
- Abstract
No abstract available for this presentation
-
+
IS05.04 - Choosing Immunotherapy Alone or in Combination in 1L MNSCLC
14:45 - 15:00 | Presenter: Corey J. Langer
- Abstract
No abstract available for this presentation
-
+
IS05.05 - Q&A and Closing Remarks
15:00 - 15:15 | Presenter: Rina Hui, Roy S. Herbst, Corey J. Langer
- Abstract
No abstract available for this presentation
-
+
IS06 - Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC
- 15:30 - 16:30
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS06.01 - Welcome and Introduction
15:30 - 15:30 | Presenter: Yi-long Wu
- Abstract
No abstract available for this presentation
-
+
IS06.02 - Evolution of the NSCLC Treatment Landscape
15:30 - 15:40 | Presenter: Yi-long Wu
- Abstract
No abstract available for this presentation
-
+
IS06.03 - Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET?
15:40 - 15:55 | Presenter: Johan Vansteenkiste
- Abstract
No abstract available for this presentation
-
+
IS06.04 - Panel Discussion
15:55 - 16:07
- Abstract
No abstract available for this presentation
-
+
IS06.05 - Rethinking Inflammation to Improve Outcomes in NSCLC: Il-1 as an Emerging Target
16:07 - 16:21 | Presenter: Yasushi Goto
- Abstract
No abstract available for this presentation
-
+
IS06.06 - Q&A
16:21 - 16:29
- Abstract
No abstract available for this presentation
-
+
IS06.07 - Closing
16:29 - 16:30 | Presenter: Yi-long Wu
- Abstract
No abstract available for this presentation
-
+
IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer
- 16:45 - 17:45
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS07.01 - The Past, Present and Future of Biomarker-Driven Advanced NSCLC
16:45 - 17:15 | Presenter: Benjamin Solomon, Shirish Madhav Gadgeel, Solange Peters
- Abstract
No abstract available for this presentation
-
+
IS07.02 - Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer
17:15 - 17:45 | Presenter: Ross Soo, Solange Peters, Martin Reck
- Abstract
No abstract available for this presentation
-
+
PL01 - Opening Plenary Session (Japanese, Mandarin, Spanish Translation Available)
- 18:00 - 20:00
- 1/28/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PL01.01 - Chair
18:00 - 18:05 | Presenter: Yi-long Wu
- Abstract
No abstract available for this presentation
-
+
PL01.02 - Chair
18:05 - 18:10 | Presenter: Daniel SW Tan
- Abstract
No abstract available for this presentation
-
+
PL01.03 - Chair
18:10 - 18:10 | Presenter: Ross Soo
- Abstract
No abstract available for this presentation
-
+
PL01.04 - Lung Cancer in China
18:30 - 18:50 | Presenter: Wanqing Chen
- Abstract
No abstract available for this presentation
-
+
PL01.05 - The New WHO Classification of Lung Tumors
18:50 - 19:10 | Presenter: Ming Sound Tsao
- Abstract
Loading... -
+
PL01.06 - Molecular Epidemiology of Asian Lung Cancer
19:10 - 19:30 | Presenter: Takashi Kohno
- Abstract
Loading... -
+
PL01.07 - IASLC Distinguished Service and Lectureship Awards (Not for CME Credit)
18:10 - 18:30
- Abstract
No abstract available for this presentation
-
+
PL01.08 - Live Q&A
19:30 - 20:00
- Abstract
No abstract available for this presentation
-
+
PL01.09 - Chair
18:10 - 18:10 | Presenter: Tetsuya Mitsudomi
- Abstract
No abstract available for this presentation
